Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | Cytokines and their impact on the severity of myelofibrosis

Ruben Mesa • 22 Jun 2017
EHA 2017
Myelofibrosis

Ruben Mesa, MD, FACP, from the Mayo Cancer Clinic Center, Rochester, MN, USA, talks to us about the impact of the COMFORT I-II studies (NCT00952289) (NCT00934544) on uncovering the role and importance of cytokines with the symptoms and disease severity of myelofibrosis. He adds that this information may aid in investigating the benefit of JAK inhibition in reducing splenomegaly in myelofibrosis and potentially improving patient outcomes. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.

More from Ruben Mesa

2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
2:08
Real-world analysis of the MOST study: factors impacting progression to MF in patients with ET
Ruben Mesa • 9 Dec 2023
2:26
Assessing the impact of momelotinib on transfusion burden in MF: analysis of SIMPLIFY-1 & MOMENTUM
Ruben Mesa • 9 Dec 2023
2:20
Quantifying the anemia benefit of momelotinib in MF: analysis of data from SIMPLIFY-1 & SIMPLIFY-2
Ruben Mesa • 9 Dec 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals